CorelDRAW Technical Suite 2019 Offers Precision and Control for Technical Illustration
Enhanced isometric drawing, greater document control, improved Styles workflow, and boosted performance accelerate productivity
OTTAWA, June 11, 2019 (GLOBE NEWSWIRE) -- CorelDRAW® Technical Suite 2019 is the latest edition of Corel’s comprehensive graphics suite designed to maximize technical illustration and drafting workflows. Produce precise illustrations, including assembly instructions and complex schematics from original designs or existing 3D CAD renderings. A streamlined interface and boosted performance accelerate technical communication authoring, while new tools make design creation even more precise with enhancements to callouts, dimensioning, axonometric drawing, and more.
“Knowing that productivity is paramount, CorelDRAW Technical Suite 2019 is focused on accelerating your entire technical illustration workflow,” said Klaus Vossen, Sr. Product Manager, CorelDRAW. “From opening 2D and 3D source files, photos, and documents, to publishing technical communications of virtually any kind, this complete suite enables you to work faster with precision and control.”
Ideal for users in engineering, architecture, and manufacturing, CorelDRAW Technical Suite 2019 drives technical documentation creation with accuracy and confidence.
Benefit from enhanced isometric drawing tools
Produce complex illustrations efficiently with pinpoint accuracy. Draw on projected planes and redefine drawing planes easily with enhanced projected drawing tools. Add context with enhanced projected arrows in dimensions and leader lines, and enjoy updates to the Projected Axes docker that make projected drawing workflows more intuitive.
Have more precision and control in your documents
Understand every project element at a glance. The new Objects docker provides more control over the management of objects, layers, and pages. When creating UI dashboards and icons, or working with odd pixel-sized drawings, improved pixel workflow tools ensure images have crisp edges when exporting for the web or other digital output.
Enjoy an enhanced Styles workflow
Ensure a consistent visual style across technical publications in less time with new Styles workflow enhancements. Take advantage of the ability to apply existing Style Sets as well as new preloaded Style Sets that follow S1000D technical illustration standards.
Work more efficiently with enhanced UI, performance updates, and new CorelDRAW.app
Take advantage of an interface that’s easier to navigate with the new Find and Replace docker, and new shortcuts for commonly used tools. The updated Technical Illustration Workspace groups common features and the Project tab of the Transform docker is more intuitive. Performance improvements boost startup time, document loading times, graphics rendering, text handling, and more. Plus, sign into the new CorelDRAW.app through your browser to access your .CDR and .DES files from virtually any device and create new vector designs and illustrations on the go.
Enjoy enhanced 3D repurposing with XVL Studio Corel Edition
Technical illustrators who leverage 3D designs from existing sources will benefit from a number of updates made to the integrated XVL Studio Corel Edition. Quickly find similar parts with the same attributes and highlight parts by selecting them; plus, set color separately for profile lines and fill faces of cross-sections. Find additional enhancements to notes, illustration output, and more.
Main Applications in CorelDRAW Technical Suite 2019:
- Corel DESIGNER® 2019: Precision illustration and technical design
- CorelDRAW® 2019: Vector illustration and page layout
- Corel PHOTO-PAINT® 2019: Professional image editing
- XVL Studio Corel Edition: 3D visualization and authoring
- CorelDRAW.app™: File access, collaboration, and on-the-go illustration via web browser
The suite also offers valuable content and supporting applications, including PowerTRACE® (available in CorelDRAW and Corel DESIGNER), CAPTURE™, CONNECT™ Content (available in CorelDRAW and Corel DESIGNER), Corel Font Manager™, AfterShot™ 3 HDR.
Extend the power with the optional XVL Studio 3D CAD Corel Edition 2019 add-on
Use the add-on to transform complex 3D CAD parts and assemblies into comprehensible visualizations. Embed high-resolution raster images in illustrations when outputting to Corel DESIGNER, and specify a markup by its line type. Enjoy improved support for 3D CAD file formats, plus a number of other enhancements for a more intuitive 3D CAD to illustration workflow. XVL Studio 3D CAD Corel Edition 2019 add-on is available as a separate purchase.
Offering choice and flexibility, CorelDRAW Technical Suite 2019 is available as a subscription and perpetual license.
- Subscription license: Pay a low annual fee with the flexibility to cancel if your software needs change. Get access to the latest version as long as your subscription is active.
- Perpetual license: One-time payment for permanent license ownership with no extra monthly or annual cost.
Availability and pricing:
CorelDRAW Technical Suite 2019 is now available in English, French, German, and Japanese. Subscription licenses are available for $360.00 / £299.00 / €359.40 a year. Pricing for the full version perpetual license is $999.00 / £899.99 / €999.00 and registered users of any previous CorelDRAW Technical Suite perpetual license can upgrade for US$429.00 / £439.99 / €479.00. GBP and Euro prices include VAT.
Enterprise clients can take advantage of volume licensing options and maintenance, which offer benefits including network deployment and virtualization support. For more info, visit www.coreldraw.com/business .
One of the world’s top software companies, Corel offers some of the industry’s most respected and well-known brands, including CorelDRAW, Parallels®, MindManager®, ClearSlide®, Pinnacle™, and WinZip®. Across our entire portfolio, Corel’s products give today’s knowledge workers the tools they need to achieve new levels of creativity, productivity, and success. For more information, please visit www.corel.com.
© 2019 Corel Corporation. Corel, the Corel logo, the Corel Balloon logo, CorelDRAW, AfterShot, CAPTURE, CONNECT, CorelDRAW.app, Corel DESIGNER, Corel Font Manager, Corel PHOTO-PAINT, PowerTRACE, MindManager, Pinnacle and WinZip are trademarks or registered trademarks of Corel Corporation and/or its subsidiaries in Canada, the U.S. and elsewhere. ClearSlide is a trademark or registered trademark of ClearSlide Inc., in Canada, the U.S. and elsewhere. Parallels is a trademark or registered trademark of Parallels International GmbH in Canada, the U.S. and elsewhere. All other trademarks mentioned herein are the property of their respective owners. Patents: www.corel.com/patent.
Photos accompanying this announcement are available at
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi